Zhang Laboratory - Publications

View Dr. Zhang’s complete list of published work in NCBI MyBibliography

  1. Ahmari N, Choi K, Wu J, Rizvi TA, Jackson M, Kershner LJ, Kim MO, Zhang X, Dombi E, Shern J, Hildeman DA, Ratner N. Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas. Life Sci Alliance. 2025 Dec;8(12). doi: 10.26508/lsa.202503359. Print 2025 Dec. PubMed PMID: 40992926; PubMed Central PMCID: PMC12461152. 

Zhang Laboratory

.zhanglabaims { background-color: rgba(245, 245, 245, 1); padding: 1rem; border-radius:1rem; border: 1px solid #ccc; }

Research Overview

The Molecular Cancer Prevention Laboratory, led by Dr. Xiyuan Zhang at the Rutgers Cancer Institute, leverages genome-wide sequencing technologies to decipher the etiology and progression of pediatric sarcomas and cancer predisposition syndromes, particularly neurofibromatosis type 1 (NF1).

Physician Profile

Stephanie Badalamenti, MD, PhD

Stephanie Badalamenti, MD, PhD